News >

Venetoclax Spearheads Myriad of AML Advances

Kristi Rosa
Published: Wednesday, May 01, 2019

Jacqueline S. Garcia, MD

Jacqueline S. Garcia, MD

One of the most exciting advances made in the acute myeloid leukemia (AML) paradigm has been the addition of venetoclax (Venclexta), said Jacqueline S. Garcia, MD, as the agent has been shown to have high response rates with durable remissions.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication